Pfizer just announced in a press release that an 85,000-patient study conducted in the Netherlands shows that its Prevnar 13 vaccine prevents pneumonia and invasive bacterial infection in adults aged 65 and older. The news has the potential to dramatically increase the number of adults who are vaccinated against the pneumococcus bacteria. Both Prevnar 13 and an older vaccine from Merck are approved for this use by the Food and Drug Administration, but use of the vaccines has been limited because there was not proof as to how well the vaccine prevents people from becoming sick.
Help employers find you! Check out all the jobs and post your resume.
